Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Is The Corneal Endothelial Dystrophy Market Expected To Grow In Terms Of Size?

Over the last few years, the corneal endothelial dystrophy market has seen impressive growth. The market’s value, calculated at $170.96 billion in 2024, is predicted to rise to $184.84 billion in 2025, representing an 8.1% compound annual growth rate (CAGR). This historical expansion can be attributed to increased spending on healthcare, a surge in corneal endothelial dystrophy cases, a burgeoning elderly population, a rise in eye disease cases, and an uptick in instances of corneal disorders.

The size of the corneal endothelial dystrophy market is projected to experience a robust, consistent expansion in the coming years. It’s anticipated to reach a value of $250.98 billion by 2029, with a compound annual growth rate (CAGR) of 7.9%. Several factors are contributing to this anticipated surge during the forecast period, including an increase in corneal blindness in developing economies, heightened awareness of eye care needs, a surge in the need for corneal transplants, improvements in healthcare infrastructure, and a rising incidence of chronic diseases. Key trends predicted for the forecast period involve progress in regenerative therapies, advancements in the medical technology sector, the advent of superior diagnostic methods, technological innovations in ophthalmic lasers, and the development of cutting-edge technologies.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21158&type=smp

What Are The Primary Factors Supporting The Corneal Endothelial Dystrophy Market Expansion?

The corneal endothelial dystrophy market is expected to expand due to the increasing requirement for corneal transplants. This surgical operation involves substituting a sick or damaged cornea with a healthy one from a donor, thereby improving vision and overall eye health. The demand for such procedures arises from a growing incidence of corneal diseases, innovative surgical methods, and better rates of organ donation. Corneal endothelial dystrophy, a condition treated through corneal transplantation, involves replacing the affected endothelium with healthy tissue from a donor to restore corneal clarity, lessen edema and enhance vision. For example, the Eye Bank Association of America reported a 2.7% rise in domestic keratoplasty, a type of corneal transplant, from 49,597 in 2022 to 50,925 in 2023. Consequently, this rising need for corneal transplants is propelling the corneal endothelial dystrophy market forward.

Which Segmentation Categories Are Highlighted In The Corneal Endothelial Dystrophy Market Analysis?

The corneal endothelial dystrophymarket covered in this report is segmented –

1) By Treatment: Phototherapeutic Keratectomy; Amniotic Membrane Transplants; Anterior Stromal Puncture; Conjunctival Flaps

2) By Disease Type: Congenital Hereditary Endothelial Dystrophy 1; Congenital Hereditary Endothelial Dystrophy 2; Posterior Polymorphous Corneal Dystrophy; Fuchs Endothelial Corneal Dystrophy

3) By Diagnosis: Cornea Examination And Grading; Corneal Tomography; Corneal Pachymetry; Corneal Cell Count

4) By End-User: Hospitals; Clinics; Other End Users

Subsegments:

1) By Phototherapeutic Keratectomy: Excimer Laser Therapy; Corneal Reshaping

2) By Amniotic Membrane Transplants: Fresh Amniotic Membrane Transplant; Cryopreserved Amniotic Membrane Transplant

3) By Anterior Stromal Puncture: Manual Technique; Laser-Assisted Technique

4) By Conjunctival Flaps: Partial Flap Technique; Full Flap Technique

Which Market Trends Are Expected To Define The Future Of The Corneal Endothelial Dystrophy Market?

Major corporations in the corneal endothelial dystrophy industry are concentrating their efforts on introducing novel and more efficient treatment procedures like allogeneic cell therapy to fulfil the medical needs that are currently not being met. This approach entails using cells from a genetically diverse donor of the same species for treating the recipient. In an example from September 2024, a clinical-stage biotech firm from the US, Aurion Biotech Inc., introduced Vyznova (neltependocel) to manage bullous keratopathy, a type of corneal endothelial disease, in Japan. Vyznova, a cell therapy solution for bullous keratopathy developed by Aurion Biotech, has the potential to impair corneal endothelial cells and lead to vision issues. Receiving approval in Japan, it’s the first cell therapy to be approved for treating corneal endothelial diseases. The product, made with lab-grown corneal endothelial cells, can yield up to 1,000 doses from a single donor. It presents a less invasive option than corneal transplants, aiding in the shortage issue of donor corneas and opening up a new approach for restoring vision in individuals afflicted with corneal diseases.

Which Organizations Are At The Forefront Of The Corneal Endothelial Dystrophy Market?

Major companies operating in the corneal endothelial dystrophy market are F. Hoffmann-La Roche AG, Abbvie (Allergan plc), Teva Pharmaceutical Industries Ltd, Fujifilm Holdings Corporation, Alcon Inc., Bausch Health+Lomb, Santen Pharmaceutical Co., Ltd., AGC Biologics Inc, Lumenis Ltd, Aurion Biotech Inc, Carl Zeiss Meditec AG, Keeler Limited, Kowa Company Ltd., ProQR Therapeutics N.V., Cellusion Inc., OptoTech GmbH, ActualEyes Inc., Arctic Vision Inc., Aurion Biotech LLC, Emmecell S.R.L

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/corneal-endothelial-dystrophy-global-market-report

Which Geographic Regions Are Creating Strong Demand In The Corneal Endothelial Dystrophy Market?

North America was the largest region in the corneal endothelial dystrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the corneal endothelial dystrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21158&type=smp

Browse Through More Reports Similar to the Global Corneal Endothelial Dystrophy Market 2025, By The Business Research Company

Corneal Implants Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/corneal-implants-global-market-report

Vascular Endothelial Growth Factor Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/vascular-endothelial-growth-factor-inhibitors-global-market-report

Anti Vascular Endothelial Growth Factor Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anti-vascular-endothelial-growth-factor-therapeutics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model